Nektar Therapeutics (NKTR) Return on Equity (2016 - 2025)
Historic Return on Equity for Nektar Therapeutics (NKTR) over the last 15 years, with Q3 2025 value amounting to 3.73%.
- Nektar Therapeutics' Return on Equity fell 11100.0% to 3.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.73%, marking a year-over-year decrease of 11100.0%. This contributed to the annual value of 1.24% for FY2024, which is 1300.0% down from last year.
- According to the latest figures from Q3 2025, Nektar Therapeutics' Return on Equity is 3.73%, which was down 11100.0% from 22.05% recorded in Q2 2025.
- Over the past 5 years, Nektar Therapeutics' Return on Equity peaked at 22.05% during Q2 2025, and registered a low of 3.73% during Q3 2025.
- For the 5-year period, Nektar Therapeutics' Return on Equity averaged around 0.28%, with its median value being 1.36% (2024).
- Within the past 5 years, the most significant YoY rise in Nektar Therapeutics' Return on Equity was 237600bps (2025), while the steepest drop was -20900bps (2025).
- Quarter analysis of 5 years shows Nektar Therapeutics' Return on Equity stood at 0.71% in 2021, then tumbled by -36bps to 0.96% in 2022, then plummeted by -97bps to 1.9% in 2023, then decreased by -14bps to 2.17% in 2024, then plummeted by -72bps to 3.73% in 2025.
- Its last three reported values are 3.73% in Q3 2025, 22.05% for Q2 2025, and 3.45% during Q1 2025.